AGENCY: Office of the Secretary, HHS.

ACTION: Semiannual Regulatory Agenda

SUMMARY: The Regulatory Flexibility Act of 1980 and Executive Order 12866 require the Department semiannually to issue an inventory of rulemaking actions under development to provide the public a summary of forthcoming regulatory actions. This information will help the public more effectively participate in the Department’s regulatory activity, and the Department welcomes comments on any aspect of this agenda.

FOR FURTHER INFORMATION CONTACT: Jennifer M. Cannistra, Executive Secretary, Department of Health and Human Services, Washington, DC 20201.
SUPPLEMENTARY INFORMATION: The Department of Health and Human Services (HHS) is the Federal Government’s principal agency for protecting the health of all Americans and providing essential human services, especially for those who are least able to help themselves. HHS enhances the health and well-being of Americans by promoting effective health and human services and by fostering sound, sustained advances in the sciences underlying medicine, public health, and social services. This agenda presents the rulemaking activities that the Department expects to undertake in the foreseeable future to advance this mission. The agenda furthers several Departmental goals, including strengthening health care; advancing scientific knowledge and innovation; advancing the health, safety, and well-being of the American people; increasing efficiency, transparency, and accountability of HHS programs; and strengthening the nation’s health and human services infrastructure and workforce.

The purpose of the agenda is to encourage more effective public participation in the regulatory process. HHS is currently furthering this goal by engaging in a Department-wide effort to identify ways to make the rulemaking process more accessible to the general public. This effort is in response to President Obama’s January 18, 2011, Executive Order 13563, “Improving Regulation and Regulatory Review,” which requires ongoing retrospective review of current agency regulations and encourages federal agencies to develop balanced regulations through a process that “allows for public participation and an open exchange of ideas.” HHS’s efforts include stakeholder outreach and continuing to update its main regulatory webpage (http://www.HHS.gov/Regulations) with information helpful to the public. For example, to encourage public participation, the webpage includes links to HHS rules currently open for public comment and provides a “regulations toolkit” with background information on regulations, the commenting process, and how the public can provide effective comments. HHS also actively encourages meaningful public participation in retrospective review and rulemaking through education and outreach (http://www.HHS.gov/RetrospectiveReview).

The rulemaking abstracts included in this paper issue of the Federal Register only cover, as required by the Regulatory Flexibility Act of 1980, those prospective HHS rulemakings likely to have a significant
economic impact on a substantial number of small entities. The Department’s complete Regulatory Agenda is accessible online at http://www.RegInfo.gov.

Dated: April 22, 2013.

NAME: Jennifer M. Cannistra,

Executive Secretary to the Department.

Food and Drug Administration—Prerule Stage

<table>
<thead>
<tr>
<th>Sequence Number</th>
<th>Title</th>
<th>Regulation Identifier Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Over-the-Counter (OTC) Drug Review—Sunscreen Products</td>
<td>0910–AF43</td>
</tr>
<tr>
<td>2</td>
<td>Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements, and Administrative Procedures (Section 610 Review)</td>
<td>0910–AG14</td>
</tr>
</tbody>
</table>

Food and Drug Administration—Proposed Rule Stage

<table>
<thead>
<tr>
<th>Sequence Number</th>
<th>Title</th>
<th>Regulation Identifier Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Food Labeling; Revision of the Nutrition and Supplement Facts Labels</td>
<td>0910–AF22</td>
</tr>
<tr>
<td>4</td>
<td>Serving Sizes of Foods That Can Reasonably Be Consumed in One Eating Occasion; Dual Column Labeling; Updating, Modifying and Establishing Certain Reference Amounts</td>
<td>0910–AF23</td>
</tr>
<tr>
<td>5</td>
<td>Over-the-Counter (OTC) Drug Review—Cough/Cold (Antihistamine) Products</td>
<td>0910–AF31</td>
</tr>
<tr>
<td>6</td>
<td>Over-the-Counter (OTC) Drug Review—Internal Analgesic Products</td>
<td>0910–AF36</td>
</tr>
<tr>
<td>7</td>
<td>Over-the-Counter (OTC) Drug Review—Topical Antimicrobial Drug Products</td>
<td>0910–AF69</td>
</tr>
<tr>
<td>8</td>
<td>Laser Products; Proposed Amendment to Performance Standard</td>
<td>0910–AF87</td>
</tr>
<tr>
<td>9</td>
<td>Updated Standards for Labeling of Pet Food</td>
<td>0910–AG09</td>
</tr>
<tr>
<td>10</td>
<td>Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals</td>
<td>0910–AG10</td>
</tr>
<tr>
<td>11</td>
<td>Over-the-Counter (OTC) Drug Review—Pediatric Dosing for Cough/Cold Products</td>
<td>0910–AG12</td>
</tr>
<tr>
<td>12</td>
<td>Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products</td>
<td>0910–AG18</td>
</tr>
<tr>
<td>13</td>
<td>Amendment to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals—Second Phase</td>
<td>0910–AG20</td>
</tr>
<tr>
<td>14</td>
<td>Produce Safety Regulation</td>
<td>0910–AG35</td>
</tr>
<tr>
<td>15</td>
<td>Hazard Analysis and Risk-Based Preventive Controls</td>
<td>0910–AG36</td>
</tr>
<tr>
<td>16</td>
<td>“Tobacco Products” Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act</td>
<td>0910–AG38</td>
</tr>
<tr>
<td>17</td>
<td>Requirements for the Testing and Reporting of Tobacco Product Constituents, Ingredients, and Additives</td>
<td>0910–AG59</td>
</tr>
<tr>
<td>18</td>
<td>Foreign Supplier Verification Program</td>
<td>0910–AG64</td>
</tr>
<tr>
<td>19</td>
<td>Amendments to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals—Components</td>
<td>0910–AG70</td>
</tr>
<tr>
<td>Sequence Number</td>
<td>Title</td>
<td>Regulation Identifier</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>20</td>
<td>Requirements for the Submission of Data Needed to Calculate User Fees for Manufacturers and Importers of Tobacco Products</td>
<td>0910–AG81</td>
</tr>
<tr>
<td>21</td>
<td>Food Labeling: Serving Sizes; Reference Amount and Serving Size Declaration for Hard Candies and Breath Mints</td>
<td>0910–AG82</td>
</tr>
<tr>
<td>22</td>
<td>Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products</td>
<td>0910–AG94</td>
</tr>
<tr>
<td>23</td>
<td>Veterinary Feed Directive</td>
<td>0910–AG95</td>
</tr>
<tr>
<td>24</td>
<td>Format and Content of Reports Intended to Demonstrate Substantial Equivalence</td>
<td>0910–AG96</td>
</tr>
<tr>
<td>25</td>
<td>Radiology Devices; Designation of Special Controls for the Computed Tomography X-Ray System</td>
<td>0910–AH03</td>
</tr>
<tr>
<td>26</td>
<td>Mammography Quality Standards Act; Regulatory Amendments</td>
<td>0910–AH04</td>
</tr>
</tbody>
</table>

**Food and Drug Administration—Final Rule Stage**

<table>
<thead>
<tr>
<th>Sequence Number</th>
<th>Title</th>
<th>Regulation Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>Content and Format of Labeling for Human Prescription Drugs and Biologics; Requirements for Pregnancy and Lactation Labeling</td>
<td>0910–AF11</td>
</tr>
<tr>
<td>28</td>
<td>Infant Formula: Current Good Manufacturing Practices; Quality Control Procedures; Notification Requirements; Records and Reports; and Quality Factors</td>
<td>0910–AF27</td>
</tr>
<tr>
<td>29</td>
<td>Over-the-Counter (OTC) Drug Review—Cough/Cold (Combination) Products</td>
<td>0910–AF33</td>
</tr>
<tr>
<td>30</td>
<td>Unique Device Identification</td>
<td>0910–AG31</td>
</tr>
<tr>
<td>31</td>
<td>Food Labeling: Calorie Labeling of Articles of Food Sold in</td>
<td>0910–AG56</td>
</tr>
</tbody>
</table>
### Vending Machines

<table>
<thead>
<tr>
<th>Sequence Number</th>
<th>Title</th>
<th>Regulation Identifier Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>32</td>
<td>Food Labeling: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments</td>
<td>0910–AG57</td>
</tr>
<tr>
<td>33</td>
<td>Use of Certain Symbols in Labeling</td>
<td>0910–AG74</td>
</tr>
<tr>
<td>34</td>
<td>Food Labeling; Gluten-Free Labeling of Foods</td>
<td>0910–AG84</td>
</tr>
</tbody>
</table>

### Food and Drug Administration—Long-Term Actions

<table>
<thead>
<tr>
<th>Sequence Number</th>
<th>Title</th>
<th>Regulation Identifier Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>35</td>
<td>Human Subject Protection; Acceptance of Data From Clinical Studies for Medical Devices</td>
<td>0910–AG48</td>
</tr>
</tbody>
</table>

### Food and Drug Administration—Completed Actions

<table>
<thead>
<tr>
<th>Sequence Number</th>
<th>Title</th>
<th>Regulation Identifier Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>36</td>
<td>Food Labeling: Serving Sizes; Reference Amounts for Candies</td>
<td>0910–AG83</td>
</tr>
</tbody>
</table>

### Centers for Medicare & Medicaid Services—Proposed Rule Stage

<table>
<thead>
<tr>
<th>Sequence Number</th>
<th>Title</th>
<th>Regulation Identifier Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>37</td>
<td>Emergency Preparedness Requirements for Medicare and Medicaid Participating Providers and Suppliers (CMS-3178-P) (Section 610 Review)</td>
<td>0938–AO91</td>
</tr>
<tr>
<td>38</td>
<td>Changes to the Hospital Outpatient Prospective Payment System</td>
<td>0938–AR54</td>
</tr>
<tr>
<td>Sequence Number</td>
<td>Title</td>
<td>Regulation Identifier Number</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>39</td>
<td>Revisions to Payment Policies Under the Physician Fee Schedule and Medicare Part B for CY 2014 (CMS-1600-P)</td>
<td>0938–AR56</td>
</tr>
<tr>
<td>40</td>
<td>Prospective Payment System for Federally Qualified Health Centers (FQHCs) (CMS-1443-P) <em>(Section 610 Review)</em></td>
<td>0938–AR62</td>
</tr>
</tbody>
</table>

**Centers for Medicare & Medicaid Services—Final Rule Stage**

<table>
<thead>
<tr>
<th>Sequence Number</th>
<th>Title</th>
<th>Regulation Identifier Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>41</td>
<td>Covered Outpatient Drugs (CMS-2345-F) <em>(Section 610 Review)</em></td>
<td>0938–AQ41</td>
</tr>
<tr>
<td>42</td>
<td>Changes to the Hospital Inpatient and Long-Term Care Prospective Payment System for FY 2014 (CMS-1599-F)</td>
<td>0938–AR53</td>
</tr>
</tbody>
</table>

**Centers for Medicare & Medicaid Services—Completed Actions**

<table>
<thead>
<tr>
<th>Sequence Number</th>
<th>Title</th>
<th>Regulation Identifier Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>43</td>
<td>Transparency Reports and Reporting of Physician Ownership of Investment Interests (CMS-5060-F)</td>
<td>0938–AR33</td>
</tr>
<tr>
<td>44</td>
<td>Part B Inpatients Billings in Hospitals (CMS-1455-F)</td>
<td>0938–AR73</td>
</tr>
</tbody>
</table>

**Department of Health and Human Services (HHS) Prerule Stage**

**Food and Drug Administration (FDA)**
1. OVER–THE–COUNTER (OTC) DRUG REVIEW—SUNSCREEN PRODUCTS

Legal Authority: 21 USC 321p; 21 USC 331; 21 USC 351 to 353; 21 USC 355; 21 USC 360; 21 USC 371

Abstract: The OTC drug review establishes conditions under which OTC drugs are considered generally recognized as safe and effective and not misbranded. After a final monograph (i.e., final rule) is issued, only OTC drugs meeting the conditions of the monograph, or having an approved new drug application, may be legally marketed. The first of the future actions will address the safety of sunscreen active ingredients.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANPRM (Sunscreen and Insect Repellent)</td>
<td>02/22/07</td>
<td>72 FR 7941</td>
</tr>
<tr>
<td>ANPRM Comment Period End</td>
<td>05/23/07</td>
<td></td>
</tr>
<tr>
<td>NPRM (UVA/UVB)</td>
<td>08/27/07</td>
<td>72 FR 49070</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>12/26/07</td>
<td></td>
</tr>
<tr>
<td>Final Action (UVA/UVB)</td>
<td>06/17/11</td>
<td>76 FR 35620</td>
</tr>
<tr>
<td>NPRM (Effectiveness)</td>
<td>06/17/11</td>
<td>76 FR 35672</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>09/15/11</td>
<td></td>
</tr>
<tr>
<td>ANPRM (Dosage Forms)</td>
<td>06/17/11</td>
<td>76 FR 35669</td>
</tr>
<tr>
<td>ANPRM Comment Period End</td>
<td>09/15/11</td>
<td></td>
</tr>
<tr>
<td>ANPRM (Safety)</td>
<td>11/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: David Eng, Regulatory Project Manager, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 22, Room 5487, 10903 New Hampshire Avenue, Silver Spring, MD 20993
2. PRESCRIPTION DRUG MARKETING ACT OF 1987; PRESCRIPTION DRUG AMENDMENTS OF 1992; POLICIES, REQUIREMENTS, AND ADMINISTRATIVE PROCEDURES (SECTION 610 REVIEW)

Legal Authority: 21 USC 331; 21 USC 333; 21 USC 351 to 353; 21 USC 360; 21 USC 371; 21 USC 374; 21 USC 381

Abstract: FDA is currently reviewing regulations promulgated under the Prescription Drug Marketing Act (PDMA). FDA is undertaking this review to determine whether the regulations should be changed or rescinded to minimize adverse impacts on a substantial number of small entities. FDA has extended again the completion date by 1 year and will complete the review by November 2013.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>Begin Review of Current Regulation</td>
<td>11/24/08</td>
<td></td>
</tr>
<tr>
<td>End Review of Current Regulation</td>
<td>11/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Howard Muller, Office of Regulatory Policy, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 6234, 10903 New Hampshire Avenue, Silver Spring, MD 20993–0002

Phone: 301 796–3601
Fax: 301 847–8440
Email: pdma610(c)review@fda.hhs.gov

RIN: 0910–AG14
3. FOOD LABELING; REVISION OF THE NUTRITION AND SUPPLEMENT FACTS LABELS

Legal Authority: 21 USC 321; 21 USC 343; 21 USC 371

Abstract: FDA is proposing to amend the labeling regulations for conventional foods and dietary supplements to provide updated nutrition information on the label to assist consumers in maintaining healthy dietary practices. If finalized, this rule will modernize the nutrition information found on the Nutrition Facts label, as well as the format and appearance of the label.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANPRM</td>
<td>07/11/03</td>
<td>68 FR 41507</td>
</tr>
<tr>
<td>ANPRM Comment Period End</td>
<td>10/09/03</td>
<td></td>
</tr>
<tr>
<td>Second ANPRM</td>
<td>04/04/05</td>
<td>70 FR 17008</td>
</tr>
<tr>
<td>Second ANPRM Comment Period End</td>
<td>06/20/05</td>
<td></td>
</tr>
<tr>
<td>Third ANPRM</td>
<td>11/02/07</td>
<td>72 FR 62149</td>
</tr>
<tr>
<td>Third ANPRM Comment Period End</td>
<td>01/31/08</td>
<td></td>
</tr>
<tr>
<td>NPRM</td>
<td>11/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Blakeley Fitzpatrick, Interdisciplinary Scientist, Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition (HFS–830), HFS–830, 5100 Paint Branch Parkway, College Park, MD 20740

Phone: 240 402–1450

Email: blakeley.fitzpatrick@fda.hhs.gov
4. SERVING SIZES OF FOODS THAT CAN REASONABLY BE CONSUMED IN ONE EATING OCCASION; DUAL COLUMN LABELING; UPDATING, MODIFYING AND ESTABLISHING CERTAIN REFERENCE AMOUNTS CUSTOMARILY CONSUMED

Legal Authority: 21 USC 321; 21 USC 343; 21 USC 371

Abstract: FDA is proposing to amend its labeling regulations for foods to provide updated Reference Amounts Customarily Consumed (RACCs) for certain food categories. If finalized, this rule would provide consumers with nutrition information based on the amount of food that is customarily consumed, which would assist consumers in maintaining healthy dietary practices. In addition to updating certain RACCs, FDA is also considering amending the definition of single-serving containers and providing for dual-column labeling, which would provide nutrition information per serving and per container, for certain containers.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANPRM</td>
<td>04/04/05</td>
<td>70 FR 17010</td>
</tr>
<tr>
<td>ANPRM Comment Period End</td>
<td>06/20/05</td>
<td></td>
</tr>
<tr>
<td>NPRM</td>
<td>11/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Cherisa Henderson, Nutritionist, Department of Health and Human Services, Food and Drug Administration, HFS–830, 5100 Paint Branch Parkway, College Park, MD 20740

Phone: 202 402–1450
Fax: 301 436–1191
Email: cherisa.henderson@fda.hhs.gov

RIN: 0910–AF23

5. OVER–THE–COUNTER (OTC) DRUG REVIEW—COUGH/COLD (ANTIHISTAMINE) PRODUCTS
Legal Authority: 21 USC 321p; 21 USC 331; 21 USC 351 to 353; 21 USC 355; 21 USC 360; 21 USC 371

Abstract: FDA will be proposing a rule to add the common cold indication to certain over-the-counter (OTC) antihistamine active ingredients. This proposed rule is the result of collaboration under the U.S.-Canada Regulatory Cooperation Council (RCC) as part of efforts to reduce unnecessary duplication and differences. This pilot exercise will help determine the feasibility of developing an ongoing mechanism for alignment in review and adoption of OTC drug monograph elements.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reopening of Administrative</td>
<td>08/25/00</td>
<td>65 FR 51780</td>
</tr>
<tr>
<td>Record</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comment Period End</td>
<td>11/24/00</td>
<td></td>
</tr>
<tr>
<td>NPRM (Amendment) (Common Cold)</td>
<td>11/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Janice Adams–King, Regulatory Health Project Manager, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 22, Room 5416, 10903 New Hampshire Avenue, Silver Spring, MD 20993

Phone: 301 796–3713
Fax: 301 796–9899
Email: janice.adams-king@fda.hhs.gov

RIN: 0910–AF31

6. OVER–THE–COUNTER (OTC) DRUG REVIEW—INTERNAL ANALGESIC PRODUCTS

Legal Authority: 21 USC 321p; 21 USC 331; 21 USC 351 to 353; 21 USC 355; 21 USC 360; 21 USC 371; 21 USC 374; 21 USC 379e

Abstract: The OTC drug review establishes conditions under which OTC drugs are considered generally recognized as safe and effective and not misbranded. After a final monograph (i.e., final rule) is issued,
only OTC drugs meeting the conditions of the monograph, or having an approved new drug application, may be legally marketed. The first action addresses acetaminophen safety. The second action addresses products marketed for children under 2 years old and weight- and age-based dosing for children’s products.

**Timetable:**

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM (Amendment)</td>
<td>12/26/06</td>
<td>71 FR 77314</td>
</tr>
<tr>
<td>(Required Warnings and Other Labeling)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>05/25/07</td>
<td></td>
</tr>
<tr>
<td>Final Action (Required Warnings and Other Labeling)</td>
<td>04/29/09</td>
<td>74 FR 19385</td>
</tr>
<tr>
<td>Final Action (Correction)</td>
<td>06/30/09</td>
<td>74 FR 31177</td>
</tr>
<tr>
<td>Final Action (Technical Amendment)</td>
<td>11/25/09</td>
<td>74 FR 61512</td>
</tr>
<tr>
<td>NPRM (Amendment) (Acetaminophen)</td>
<td>12/00/13</td>
<td></td>
</tr>
<tr>
<td>NPRM (Amendment) (Pediatric)</td>
<td>12/00/13</td>
<td></td>
</tr>
</tbody>
</table>

**Regulatory Flexibility Analysis Required:** Yes

**Agency Contact:** Janice Adams–King, Regulatory Health Project Manager, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 22, Room 5416, 10903 New Hampshire Avenue, Silver Spring, MD 20993

Phone: 301 796–3713
Fax: 301 796–9899
Email: janice.adams-king@fda.hhs.gov

**RIN:** 0910–AF36
7. OVER–THE–COUNTER (OTC) DRUG REVIEW—TOPICAL ANTIMICROBIAL DRUG PRODUCTS

Legal Authority: 21 USC 321p; 21 USC 331; 21 USC 351 to 353; 21 USC 355; 21 USC 360; 21 USC 371

Abstract: The OTC drug review establishes conditions under which OTC drugs are considered generally recognized as safe and effective and not misbranded. After a final monograph (i.e., final rule) is issued, only OTC drugs meeting the conditions of the monograph, or having an approved new drug application, may be legally marketed. This action addresses antimicrobial agents in consumer hand wash products.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM (Healthcare)</td>
<td>06/17/94</td>
<td>59 FR 31402</td>
</tr>
<tr>
<td>Comment Period End</td>
<td>12/15/95</td>
<td></td>
</tr>
<tr>
<td>NPRM (Consumer Hand Wash Products)</td>
<td>09/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: David Eng, Regulatory Project Manager, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 22, Room 5487, 10903 New Hampshire Avenue, Silver Spring, MD 20993

Phone: 301 796–2773
Fax: 301 796–9899
Email: david.eng@fda.hhs.gov

RIN: 0910–AF69

8. LASER PRODUCTS; PROPOSED AMENDMENT TO PERFORMANCE STANDARD

Legal Authority: 21 USC 360hh to 360ss; 21 USC 371; 21 USC 393

Abstract: FDA is proposing to amend the performance standard for laser products to achieve closer harmonization between the current standard and the International Electrotechnical Commission (IEC)
standard for laser products and medical laser products. The proposed amendment is intended to update
FDA's performance standard to reflect advancements in technology.

**Timetable:**

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>06/24/13</td>
<td>78 FR 37723</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>09/23/13</td>
<td></td>
</tr>
</tbody>
</table>

**Regulatory Flexibility Analysis Required:** Yes

**Agency Contact:** Nancy Pirt, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, WO 66, Room 4438, 10903 New Hampshire Avenue, Silver Spring, MD 20993
Phone: 301 796–6248
Fax: 301 847–8145
Email: nancy.pirt@fda.hhs.gov

**RIN:** 0910–AF87

---

**9. UPDATED STANDARDS FOR LABELING OF PET FOOD**

**Legal Authority:** 21 USC 343; 21 USC 371; PL 110–85, sec 1002(a)(3)

**Abstract:** FDA is proposing updated standards for the labeling of pet food that include nutritional and ingredient information, as well as style and formatting standards. FDA is taking this action to provide pet owners and animal health professionals more complete and useful information about the nutrient content and ingredient composition of pet food products.

**Timetable:**

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>04/00/14</td>
<td></td>
</tr>
</tbody>
</table>

**Regulatory Flexibility Analysis Required:** Yes

**Agency Contact:** William Burkholder, Veterinary Medical Officer, Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine, Room 2642 (MPN–4, HFV–228), 7519 Standish Place, Rockville, MD 20855
10. CURRENT GOOD MANUFACTURING PRACTICE, HAZARD ANALYSIS, AND RISK–BASED PREVENTIVE CONTROLS FOR FOOD FOR ANIMALS

Legal Authority: 21 USC 321; 21 USC 331; 21 USC 342; 21 USC 350c; 21 USC 350d note; 21 USC 350g; 21 USC 350g note; 21 USC 371; 21 USC 374; 42 USC 264; 42 USC 243; 42 USC 271; . . .

Abstract: FDA is proposing regulations for preventive controls for animal food, including ingredients and mixed animal feed. This action is intended to provide greater assurance that food marketed for all animals, including pets, is safe.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>08/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Kim Young, Deputy Director, Division of Compliance, Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine, Room 106 (MPN–4, HFV–230), 7519 Standish Place, Rockville, MD 20855

Phone: 240 276–9207

Email: kim.young@fda.hhs.gov

RIN: 0910–AG10

11. OVER–THE–COUNTER (OTC) DRUG REVIEW—PEDIATRIC DOSING FOR COUGH/COLD PRODUCTS

Legal Authority: 21 USC 331; 21 USC 351 to 353; 21 USC 355; 21 USC 360; 21 USC 371

Abstract: The OTC drug review establishes conditions under which OTC drugs are considered generally recognized as safe and effective and not misbranded. After a final monograph (i.e., final rule) is issued, only OTC drugs meeting the conditions of the monograph, or having an approved new drug application,
may be legally marketed. This action will propose changes to the final monograph to address safety and efficacy issues associated with pediatric cough and cold products.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>11/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Janice Adams–King, Regulatory Health Project Manager, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 22, Room 5416, 10903 New Hampshire Avenue, Silver Spring, MD 20993

Phone: 301 796–3713

Fax: 301 796–9899

Email: janice.adams-king@fda.hhs.gov

RIN: 0910–AG12

12. ELECTRONIC DISTRIBUTION OF PRESCRIBING INFORMATION FOR HUMAN PRESCRIPTION DRUGS INCLUDING BIOLOGICAL PRODUCTS

Legal Authority: 21 USC 321; 21 USC 331; 21 USC 351; 21 USC 352; 21 USC 353; 21 USC 355; 21 USC 358; 21 USC 360; 21 USC 360b; 21 USC 360gg to 360ss; 21 USC 371; 21 USC 374; 21 USC 379e; 42 USC 216; 42 USC 241; 42 USC 262; 42 USC 264

Abstract: This rule would require electronic package inserts for human drug and biological prescription products with limited exceptions, in lieu of paper, which is currently used. These inserts contain prescribing information intended for healthcare practitioners. This would ensure that the information accompanying the product is the most up-to-date information regarding important safety and efficacy issues about these products.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>10/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes
Agency Contact: Janet Norden, Consumer Safety Officer, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 6324, 10903 New Hampshire Avenue, Silver Spring, MD 20993–0002
Phone: 301 796–2500
Email: janet.norden@fda.hhs.gov
RIN: 0910–AG18

13. AMENDMENT TO THE CURRENT GOOD MANUFACTURING PRACTICE REGULATIONS FOR FINISHED PHARMACEUTICALS—SECOND PHASE

Legal Authority: 21 USC 321; 21 USC 351; 21 USC 352; 21 USC 355; 21 USC 360b; 21 USC 371; 21 USC 374; 42 USC 262; 42 USC 264

Abstract: FDA will revise regulations for “current good manufacturing practice” for oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products. This revision will update and harmonize requirements and improve detection and response to emerging product safety and quality signals.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>01/00/14</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Paula Katz, Regulatory Counsel, Office of Compliance, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 4314, 10903 New Hampshire Avenue, Silver Spring, MD 20993
Phone: 301 796–6972
Fax: 301 847–8742
Email: paula.katz@fda.hhs.gov
RIN: 0910–AG20
14. PRODUCE SAFETY REGULATION

Legal Authority: 21 USC 342; 21 USC 350h; 21 USC 371; 42 USC 264; PL 111–353 (signed on Jan. 4, 2011)

Abstract: FDA is proposing to establish science-based minimum standards for the safe production and harvesting of those types of fruits and vegetables that are raw agricultural commodities for which the Secretary has determined that such standards minimize the risk of serious adverse health consequences or death. The purpose of the proposed rule is to reduce the risk of illness associated with fresh produce.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>01/16/13</td>
<td>78 FR 3503</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>05/16/13</td>
<td></td>
</tr>
<tr>
<td>NPRM Comment Period Extended</td>
<td>04/26/13</td>
<td>78 FR 24692</td>
</tr>
<tr>
<td>NPRM Comment Period Extended End</td>
<td>09/16/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Samir Assar, Supervisory Consumer Safety Officer, Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Food Safety, 5100 Paint Branch Parkway, College Park, MD 20740

Phone: 240 402–1636

Email: samir.assar@fda.hhs.gov

RIN: 0910–AG35

15. HAZARD ANALYSIS AND RISK–BASED PREVENTIVE CONTROLS

Legal Authority: 21 USC 342; 21 USC 371; 42 USC 264; PL 111–353 (signed on Jan. 4, 2011)

Abstract: This proposed rule would require a food facility to have and implement preventive controls to significantly minimize or prevent the occurrence of hazards that could affect food manufactured,
processed, packed, or held by the facility. This action is intended to prevent or, at a minimum, quickly identify foodborne pathogens before they get into the food supply.

**Timetable:**

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>01/16/13</td>
<td>78 FR 3646</td>
</tr>
<tr>
<td>NPRM Comment Period</td>
<td>04/26/13</td>
<td>78 FR 24691</td>
</tr>
<tr>
<td>Extended</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>09/16/13</td>
<td></td>
</tr>
</tbody>
</table>

**Regulatory Flexibility Analysis Required:** Yes

**Agency Contact:** Jenny Scott, Senior Advisor, Department of Health and Human Services, Food and Drug Administration, Office of Food Safety, 5100 Paint Branch Parkway, College Park, MD 20740

Phone: 240 402–1488

Email: jenny.scott@fda.hhs.gov

RIN: 0910–AG36

---

16. **“TOBACCO PRODUCTS” SUBJECT TO THE FEDERAL FOOD, DRUG, AND COSMETIC ACT, AS AMENDED BY THE FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT**


**Abstract:** The Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) provides the Food and Drug Administration (FDA) authority to regulate cigarettes, cigarette tobacco, roll-your-own tobacco, and smokeless tobacco. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Tobacco Control Act, permits FDA to issue regulations deeming other tobacco products to be subject to the FD&C Act. This proposed rule would deem products meeting the statutory definition of “tobacco product” to be subject to the FD&C Act and would specify additional restrictions.

**Timetable:**

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---
17. REQUIREMENTS FOR THE TESTING AND REPORTING OF TOBACCO PRODUCT CONSTITUENTS, INGREDIENTS, AND ADDITIVES

Legal Authority: 21 USC 301 et seq, 21 USC 387, The Family Smoking Prevention and Tobacco Control Act

Abstract: The Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking Prevention and Tobacco Control Act, requires the Food and Drug Administration to promulgate regulations that require the testing and reporting of tobacco product constituents, ingredients, and additives, including smoke constituents, that the agency determines should be tested to protect the public health.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>12/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Carol Drew, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products, 9200 Corporate Boulevard, Room 240 H, Rockville, MD 20850

Phone: 877 287–1373

Fax: 240 276–3904

Email: carol.drew@fda.hhs.gov

RIN: 0910–AG59
18. FOREIGN SUPPLIER VERIFICATION PROGRAM


Abstract: FDA is proposing regulations that describe what a food importer must do to verify that its foreign suppliers produce food that is as safe as food produced in the United States. FDA is taking this action to improve the safety of food that is imported into the United States.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>07/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Brian L. Pendleton, Senior Policy Advisor, Department of Health and Human Services, Food and Drug Administration, Office of Policy, WO 32, Room 4245, 10903 New Hampshire Avenue, Silver Spring, MD 20993–0002
Phone: 301 796–4614
Fax: 301 847–8616
Email: brian.pendleton@fda.hhs.gov
RIN: 0910–AG64

19. AMENDMENTS TO THE CURRENT GOOD MANUFACTURING PRACTICE REGULATIONS FOR FINISHED PHARMACEUTICALS—COMPONENTS

Legal Authority: 21 USC 321; 21 USC 351; 21 USC 352; 21 USC 355; 21 USC 360b; 21 USC 360bbb–7; 21 USC 371; 21 USC 374; 42 USC 262; 42 USC 264

Abstract: FDA will revise regulations for “current good manufacturing practice” with regard to the control over components used in manufacturing finished pharmaceuticals.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
</table>
Regulatory Flexibility Analysis Required: Yes

Agency Contact: Brian Hasselbalch, Consumer Safety Officer, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 4364, 10903 New Hampshire Avenue, Silver Spring, MD 20993
Phone: 301 796–3279
Email: brian.hasselbalch@fda.hhs.gov

Paula Katz, Consumer Safety Officer, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 1320, 10903 New Hampshire Avenue, Silver Spring, MD 20993
Phone: 301 796–6972
Email: paula.katz@fda.hhs.gov

RIN: 0910–AG70

20. REQUIREMENTS FOR THE SUBMISSION OF DATA NEEDED TO CALCULATE USER FEES FOR MANUFACTURERS AND IMPORTERS OF TOBACCO PRODUCTS

Legal Authority: 21 USC 371; 21 USC 387s; PL 111–31

Abstract: FDA is proposing to require manufacturers and importers of tobacco products to submit certain market share data to FDA. USDA currently collects such data, but its program sunsets at the end of September 2014 and USDA will cease collection of this information. FDA is taking this action so that it may continue to calculate market share percentages needed to compute user fees.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>05/31/13</td>
<td>78 FR 32581</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>08/14/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes
Agency Contact: Annette L. Marthaler, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products, Room 340K, 9200 Corporate Boulevard, Rockville, MD 20850
Phone: 877 287–1373
Fax: 240 276–3904
Email: annette.marthaler@fda.hhs.gov
RIN: 0910–AG81

21. FOOD LABELING: SERVING SIZES; REFERENCE AMOUNT AND SERVING SIZE DECLARATION FOR HARD CANDIES AND BREATH MINTS

Legal Authority: 21 USC 321; 21 USC 343; 21 USC 371

Abstract: FDA is proposing to change the nutrition label serving size for breath mints to one unit. FDA is taking this action in response to a citizen petition that requested a serving size for breath mints that more accurately reflects the amount customarily consumed per eating occasion and comments received on an advance notice of proposed rulemaking published in 2005.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>12/30/97</td>
<td>62 FR 67775</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>03/16/98</td>
<td></td>
</tr>
<tr>
<td>ANPRM</td>
<td>04/05/05</td>
<td>70 FR 17010</td>
</tr>
<tr>
<td>ANPRM Comment Period End</td>
<td>06/20/05</td>
<td></td>
</tr>
<tr>
<td>NPRM</td>
<td>07/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Mark Kantor, Nutritionist, Department of Health and Human Services, Food and Drug Administration, HFS–830, 5100 Paint Branch Parkway, College Park, MD 20740
Phone: 240 402–1450
Fax: 301 436–1191
22. • SUPPLEMENTAL APPLICATIONS PROPOSING LABELING CHANGES FOR APPROVED DRUGS AND BIOLOGICAL PRODUCTS

Legal Authority: 21 USC 321; 21 USC 331; 21 USC 352; 21 USC 353; 21 USC 355; 21 USC 371; 42 USC 262; . . .

Abstract: This proposed rule would amend the regulations regarding new drug applications (NDAs), abbreviated new drug applications (ANDAs), and biologics license applications (BLAs) to revise and clarify procedures for changes to the labeling of an approved drug to reflect certain types of newly acquired information in advance of FDA's review of such change. The proposed rule would describe the process by which information regarding a "changes being effected" (CBE) labeling supplement submitted by an NDA or ANDA holder would be made publicly available during FDA's review of the labeling change. The proposed rule also would clarify requirements for the NDA holder for the reference listed drug and all ANDA holders to submit conforming labeling revisions after FDA has taken an action on the NDA and/or ANDA holder's CBE labeling supplement. These proposed revisions to FDA's regulations would create parity between NDA holders and ANDA holders with respect to submission of CBE labeling supplements.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>09/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Janice L. Weiner, Senior Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 6304, 10903 New Hampshire Avenue, Silver Spring, MD 20993–0002

Phone: 301 796–3601

Fax: 301 847–8440

Email: janice.weiner@fda.hhs.gov

RIN: 0910–AG94
23. • VETERINARY FEED DIRECTIVE

Legal Authority: 21 USC 354; 21 USC 360b; 21 USC 360ccc; 21 USC 360ccc –1; 21 USC 371

Abstract: The Animal Drug Availability Act created a new category of products called veterinary feed directive drugs (VFD drugs). This rulemaking is intended to provide for the increased efficiency of the VFD program.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANPRM</td>
<td>03/29/10</td>
<td>75 FR 15387</td>
</tr>
<tr>
<td>ANPRM Comment Period End</td>
<td>06/28/10</td>
<td></td>
</tr>
<tr>
<td>NPRM</td>
<td>09/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Sharon Benz, Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine, MPN–4, Room 2648, HFV–220, 7529 Standish Place, Rockville, MD 20855
Phone: 240 453–6864
Email: sharon.benz@fda.hhs.gov

RIN: 0910–AG95

24. • FORMAT AND CONTENT OF REPORTS INTENDED TO DEMONSTRATE SUBSTANTIAL EQUIVALENCE

Legal Authority: 21 USC 387e(j); 21 USC 387(j(a); secs 905(j) and 910(a) of the Federal Food, Drug, and Cosmetic Act

Abstract: This regulation would establish the format and content of reports intended to demonstrate substantial equivalence and compliance with the FD&C Act (sections 905(j) and 910(a) of the FD&C Act). This regulation also would provide information as to how the Agency will review and act on these submissions.
25. • RADILOGY DEVICES; DESIGNATION OF SPECIAL CONTROLS FOR THE COMPUTED TOMOGRAPHY X–RAY SYSTEM

Legal Authority: 21 USC 360

Abstract: The proposed rule would establish special controls for the computed tomography (CT) x-ray system, a class II device as defined in 21 CFR 892.1750. A CT x-ray system is a diagnostic x-ray imaging system intended to produce cross-sectional images of the body through use of a computer to reconstruct an image from the same axial plane taken at different angles. High doses of ionizing radiation can cause acute (deterministic) effects such as burns, reddening of the skin, cataracts, hair loss, sterility, or, in extremely high doses, radiation poisoning. Therefore, the design of a CT x-ray system needs to balance the benefits of the device (i.e., the ability of the device to produce a diagnostic quality image) with the known risks (e.g., exposure to ionizing radiation). FDA is establishing special controls, combined with the general controls, to provide reasonable assurance of the safety and effectiveness of a class II CT x-ray system.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>12/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes
Agency Contact: Erica Blake, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, WO 66, Room 4426, 10903 New Hampshire Avenue, Silver Spring, MD 20993
Phone: 301 796–6248
Fax: 301 847–8145
Email: erica.blake@fda.hhs.gov
RIN: 0910–AH03

26. • MAMMOGRAPHY QUALITY STANDARDS ACT; REGULATORY AMENDMENTS

Legal Authority: 21 USC 360i; 21 USC 360nn; 21 USC 374(e); 42 USC 263b

Abstract: FDA is proposing to amend its regulations governing mammography. The amendments would update the regulations issued under the Mammography Quality Standards Act of 1992 (MQSA). FDA is taking this action to address changes in mammography technology and mammography processes, such as breast density reporting, that have occurred since the regulations were published in 1997.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>12/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Nancy Pirt, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, WO 66, Room 4438, 10903 New Hampshire Avenue, Silver Spring, MD 20993
Phone: 301 796–6248
Fax: 301 847–8145
Email: nancy.pirt@fda.hhs.gov
RIN: 0910–AH04
27. CONTENT AND FORMAT OF LABELING FOR HUMAN PRESCRIPTION DRUGS AND BIOLOGICS; REQUIREMENTS FOR PREGNANCY AND LACTATION LABELING

Legal Authority: 21 USC 321; 21 USC 331; 21 USC 351 to 353; 21 USC 355; 21 USC 358; 21 USC 360; 21 USC 360b; 21 USC 360gg to 360ss; 21 USC 371; 21 USC 374; 21 USC 379e; 42 USC 216; 42 USC 241; 42 USC 262; 42 USC 264

Abstract: This final rule will amend the content and format of the “Pregnancy,” “Labor and delivery,” and “Nursing mothers” subsections of the “Use in Specific Populations” section of regulations regarding the labeling for human prescription drug and biological products (21 CFR 201.56 and 201.57) to better communicate risks.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>05/29/08</td>
<td>73 FR 30831</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>08/27/08</td>
<td></td>
</tr>
<tr>
<td>Final Action</td>
<td>01/00/14</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Molly Flannery, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 6246, 10903 New Hampshire Avenue, Silver Spring, MD 20993
Phone: 301 796–3543
Email: molly.flannery@fda.hhs.gov

RIN: 0910–AF11

28. INFANT FORMULA: CURRENT GOOD MANUFACTURING PRACTICES; QUALITY CONTROL PROCEDURES; NOTIFICATION REQUIREMENTS; RECORDS AND REPORTS; AND QUALITY FACTORS
Legal Authority: 21 USC 321; 21 USC 342; 21 USC 350a; 21 USC 371

Abstract: The Food and Drug Administration (FDA) is revising its infant formula regulations in 21 CFR parts 106 and 107 to establish requirements for current good manufacturing practices (CGMP), including audits; to establish requirements for quality factors; and to amend FDA's quality control procedures, notification, and record and reporting requirements for infant formula. FDA is taking this action to improve the protection of infants who consume infant formula products.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>07/09/96</td>
<td>61 FR 36154</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>12/06/96</td>
<td></td>
</tr>
<tr>
<td>NPRM Comment Period Reopened</td>
<td>04/28/03</td>
<td>68 FR 22341</td>
</tr>
<tr>
<td>NPRM Comment Period Extended</td>
<td>06/27/03</td>
<td>68 FR 38247</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>08/26/03</td>
<td></td>
</tr>
<tr>
<td>NPRM Comment Period Reopened</td>
<td>08/01/06</td>
<td>71 FR 43392</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>09/15/06</td>
<td></td>
</tr>
<tr>
<td>Final Rule</td>
<td>07/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Benson Silverman, Staff Director, Infant Formula and Medical Foods, Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition (HFS–850), 5100 Paint Branch Parkway, College Park, MD 20740

Phone: 240 402–1459

Email: benson.silverman@fda.hhs.gov

RIN: 0910–AF27

29. OVER–THE–COUNTER (OTC) DRUG REVIEW—COUGH/COLD (COMBINATION) PRODUCTS
Legal Authority: 21 USC 321p; 21 USC 331; 21 USC 351 to 353; 21 USC 355; 21 USC 360; 21 USC 371

Abstract: The OTC drug review establishes conditions under which OTC drugs are considered generally recognized as safe and effective and not misbranded. After a final monograph (i.e., final rule) is issued, only OTC drugs meeting the conditions of the monograph, or having an approved new drug application, may be legally marketed. This action addresses cough/cold drug products containing an oral bronchodilator (ephedrine and its salts) in combination with any expectorant or any oral nasal decongestant.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM (Amendment)</td>
<td>07/13/05</td>
<td>70 FR 40232</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>11/10/05</td>
<td></td>
</tr>
<tr>
<td>Final Action (Technical Amendment)</td>
<td>03/19/07</td>
<td>72 FR 12730</td>
</tr>
<tr>
<td>Final Action</td>
<td>10/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Janice Adams–King, Regulatory Health Project Manager, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 22, Room 5416, 10903 New Hampshire Avenue, Silver Spring, MD 20993

Phone: 301 796–3713

Fax: 301 796–9899

Email: janice.adams-king@fda.hhs.gov

RIN: 0910–AF33

30. UNIQUE DEVICE IDENTIFICATION

Legal Authority: 21 USC 351; 21 USC 352; 21 USC 360; 21 USC 360h; 21 USC 360i; 21 USC 360j; 21 USC 360l; 21 USC 371
**Abstract:** FDA is issuing a final rule establishing a unique device identification system for medical devices. A unique device identification system would allow healthcare professionals and others to rapidly and precisely identify a device and obtain important information concerning the device and would reduce medical errors.

**Timetable:**

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>07/10/12</td>
<td>77 FR 40735</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>11/07/12</td>
<td></td>
</tr>
<tr>
<td>Second NPRM</td>
<td>11/19/12</td>
<td>77 FR 69393</td>
</tr>
<tr>
<td>Second NPRM Comment Period End</td>
<td>12/19/13</td>
<td></td>
</tr>
<tr>
<td>Final Action</td>
<td>07/00/13</td>
<td></td>
</tr>
</tbody>
</table>

**Regulatory Flexibility Analysis Required:** Yes

**Agency Contact:** John J. Crowley, Senior Advisor for Patient Safety, Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, WO 66, Room 2315, 10903 New Hampshire Avenue, Silver Spring, MD 20993

Phone: 301 980–1936

Email: jay.crowley@fda.hhs.gov

**RIN:** 0910–AG31

---

31. **FOOD LABELING: CALORIE LABELING OF ARTICLES OF FOOD SOLD IN VENDING MACHINES**

**Legal Authority:** 21 USC 321; 21 USC 343; 21 USC 371

**Abstract:** FDA published a proposed rule to establish requirements for nutrition labeling of certain food items sold in certain vending machines. FDA also proposed the terms and conditions for vending machine operators registering to voluntarily be subject to the requirements. FDA is issuing a final rule, and taking this action to carry out section 4205 of the Patient Protection and Affordable Care Act.

**Timetable:**
32. FOOD LABELING: NUTRITION LABELING OF STANDARD MENU ITEMS IN RESTAURANTS AND SIMILAR RETAIL FOOD ESTABLISHMENTS

Legal Authority: 21 USC 321; 21 USC 343; 21 USC 371

Abstract: FDA published a proposed rule in the Federal Register to establish requirements for nutrition labeling of standard menu items in chain restaurants and similar retail food establishments. FDA also proposed the terms and conditions for restaurants and similar retail food establishments registering to voluntarily be subject to the Federal requirements. FDA is issuing a final rule, and taking this action to carry out section 4205 of the Patient Protection and Affordable Care Act.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>04/06/11</td>
<td>76 FR 19192</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>07/05/11</td>
<td></td>
</tr>
<tr>
<td>Final Action</td>
<td>09/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Daniel Reese, Food Technologist, Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition (HFS–820), 5100 Paint Branch Parkway, College Park, MD 20740

Phone: 240 402–2126

Email: daniel.reese@fda.hhs.gov

RIN: 0910–AG56
Agency Contact: Daniel Reese, Food Technologist, Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition (HFS–820), 5100 Paint Branch Parkway, College Park, MD 20740
Phone: 240 402–2126
Email: daniel.reese@fda.hhs.gov

RIN: 0910–AG57

33. USE OF CERTAIN SYMBOLS IN LABELING

Legal Authority: sec 502(c) of the Food Drug and Cosmetic Act (FD&C Act), 21 USC 352(c); sec 514(c) of FD&C Act, 21 USC 360d(c), enacted by the Food and Drug Modernization Act of 1997 (FDAMA)

Abstract: The purpose of this rule is to allow for the inclusion of certain stand-alone symbols contained in a standard that FDA recognizes, provided that such symbols are explained in a symbols glossary that contemporaneously accompanies the medical device.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>04/19/13</td>
<td>78 FR 23508</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>06/18/13</td>
<td></td>
</tr>
<tr>
<td>Final Action</td>
<td>04/00/14</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Mary Follette Story, Human Factors and Accessible Medical Technology Specialist, Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Room 2553, 10903 New Hampshire Avenue, Silver Spring, MD 20993
Phone: 301 796–1456
Email: molly.story@fda.hhs.gov

RIN: 0910–AG74

34. FOOD LABELING; GLUTEN–FREE LABELING OF FOODS
**Legal Authority:** title II of PL 108–282; 21 USC 321; 21 USC 331; 21 USC 342; 21 USC 343; 21 USC 348; 21 USC 371

**Abstract:** FDA is amending its regulations to define the term “gluten-free” for voluntary use in the labeling of foods. FDA is taking this action to assist persons who have celiac disease to more easily identify foods that they can eat while following a “gluten-free” diet.

**Timetable:**

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>01/23/07</td>
<td>72 FR 2795</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>04/23/07</td>
<td></td>
</tr>
<tr>
<td>NPRM Comment Period Reopened</td>
<td>08/03/11</td>
<td>76 FR 46671</td>
</tr>
<tr>
<td>NPRM Comment Period Reopened End</td>
<td>10/03/11</td>
<td></td>
</tr>
<tr>
<td>Final Action</td>
<td>07/00/13</td>
<td></td>
</tr>
</tbody>
</table>

**Regulatory Flexibility Analysis Required:** Yes

**Agency Contact:** Felicia Billingslea, Director, Food Labeling and Standard Staff, Department of Health and Human Services, Food and Drug Administration, Room 4D045, HFS 820, 5100 Paint Branch Parkway, College Park, MD 20740

Phone: 240 402–1803

Fax: 301 436–2636

Email: felicia.billingslea@fda.hhs.gov

**RIN:** 0910–AG84

<table>
<thead>
<tr>
<th>Department of Health and Human Services (HHS)</th>
<th>Long-Term Actions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Food and Drug Administration (FDA)</strong></td>
<td></td>
</tr>
</tbody>
</table>
35. HUMAN SUBJECT PROTECTION; ACCEPTANCE OF DATA FROM CLINICAL STUDIES FOR MEDICAL DEVICES

Legal Authority: 21 USC 321; 21 USC 331; 21 USC 351; 21 USC 352; 21 USC 360; 21 USC 360c; 21 USC 360e; 21 USC 360i; 21 USC 360j; 21 USC 371; 21 USC 374; 21 USC 381; 21 USC 393; 42 USC 264; 42 USC 271; . . .

Abstract: This rule will amend FDA’s regulations on acceptance of data from clinical studies conducted in support of a premarket approval application, humanitarian device exemption application, an investigational device exemption application, or a premarket notification submission for a medical device.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>02/25/13</td>
<td>78 FR 12664</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>05/28/13</td>
<td></td>
</tr>
<tr>
<td>Final Action</td>
<td>09/00/14</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Sheila Anne Brown, Policy Analyst, Investigational Device Exemptions Staff,
Department of Health and Human Services, Food and Drug Administration, WO 66, Room 1651, 10903 New Hampshire Avenue, Silver Spring, MD 20993
Phone: 301 796–6563
Fax: 301 847–8120
Email: sheila.brown@fda.hhs.gov

RIN: 0910–AG48

Department of Health and Human Services (HHS)

Food and Drug Administration (FDA)

36. FOOD LABELING: SERVING SIZES; REFERENCE AMOUNTS FOR CANDIES

Legal Authority: 21 USC 321; 21 USC 343; 21 USC 371
Abstract: FDA is proposing to change its serving size regulations to provide updated Reference Amounts Customarily Consumed for candies. FDA is taking this action in response to comments received on an advance notice of proposed rulemaking published in 2005. This RIN is being withdrawn from the Unified Agenda and merged with RIN 0910-AG82.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>01/08/98</td>
<td>63 FR 1078</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>02/09/98</td>
<td></td>
</tr>
<tr>
<td>ANPRM</td>
<td>04/05/05</td>
<td>70 FR 17010</td>
</tr>
<tr>
<td>ANPRM Comment Period End</td>
<td>06/20/05</td>
<td></td>
</tr>
<tr>
<td>Withdrawn</td>
<td>03/11/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Mark Kantor, Nutritionist, Department of Health and Human Services, Food and Drug Administration, HFS–830, 5100 Paint Branch Parkway, College Park, MD 20740

Phone: 240 402–1450
Fax: 301 436–1191
Email: mark.kantor@fda.hhs.gov

RIN: 0910–AG83

Department of Health and Human Services (HHS)  Proposed Rule Stage

Centers for Medicare & Medicaid Services (CMS)

37. EMERGENCY PREPAREDNESS REQUIREMENTS FOR MEDICARE AND MEDICAID

PARTICIPATING PROVIDERS AND SUPPLIERS (CMS–3178–P) (SECTION 610 REVIEW)

Legal Authority: 42 USC 1821; 42 USC 1861 (ff) (3)(B)(i)(ii); 42 USC 1913 (c)(1) et al
Abstract: This rule proposes emergency preparedness requirements for Medicare and Medicaid participating providers and suppliers to ensure that they adequately plan for both natural and man-made disasters and coordinate with Federal, State, tribal, regional and local emergency preparedness systems. This rule would ensure providers and suppliers are adequately prepared to meet the needs of patients, residents, clients, and participants during disasters and emergency situations.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>09/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Janice Graham, Health Insurance Specialist, Clinical Standards Group, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Clinical Standards and Quality, Mail Stop S3–02–01, 7500 Security Boulevard, Baltimore, MD 21244–1850
Phone: 410 786–8020
Email: janice.graham@cms.hhs.gov

RIN: 0938–AO91

38. CHANGES TO THE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM AND AMBULATORY SURGICAL CENTER PAYMENT SYSTEM FOR CY 2014 (CMS–1601–P)

Legal Authority: sec 1833 of the Social Security Act

Abstract: This proposed rule would revise the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system. The proposed rule also describes changes to the amounts and factors used to determine payment rates for services. In addition, the rule proposes changes to the Ambulatory Surgical Center Payment System list of services and rates.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>07/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes
39. REVISIONS TO PAYMENT POLICIES UNDER THE PHYSICIAN FEE SCHEDULE AND MEDICARE PART B FOR CY 2014 (CMS–1600–P)

Legal Authority: Social Security Act secs 1102, 1871, 1848

Abstract: This proposed rule would revise payment polices under the Medicare physician fee schedule, and make other policy changes to payment under Medicare Part B. These changes would be applicable to services furnished on or after January 1 annually.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>07/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Kathy Bryant, Deputy Director, Division of Practitioner Services, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Mail Stop C4–01–27, 7500 Security Boulevard, Baltimore, MD 21244

Phone: 410 786–3448

Email: kathy.bryant@cms.hhs.gov

RIN: 0938–AR56

40. PROSPECTIVE PAYMENT SYSTEM FOR FEDERALLY QUALIFIED HEALTH CENTERS (FQHCS) (CMS–1443–P) (SECTION 610 REVIEW)

Legal Authority: PL 111–148, sec 10501
Abstract: The Affordable Care Act amends the current Medicare FQHC payment policy by requiring the establishment of a new payment system, effective with cost reporting periods beginning on or after October 1, 2014. This rule proposes the establishment of the new prospective payment system.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>09/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Sarah Harding, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Mail Stop C4–01–26, 7500 Security Boulevard, Windsor Mill, MD 21244

Phone: 410 786–4001

Email: sarah.harding@cms.hhs.gov

RIN: 0938–AR62

41. COVERED OUTPATIENT DRUGS (CMS–2345–F) (SECTION 610 REVIEW)

Legal Authority: PL 111–48, secs 2501, 2503, 3301(d)(2); PL 111–152, sec 1206; PL 111–8, sec 221

Abstract: This final rule revises requirements pertaining to Medicaid reimbursement for covered outpatient drugs to implement provisions of the Affordable Care Act. This rule also revises other requirements related to covered outpatient drugs, including key aspects of Medicaid coverage, payment, and the drug rebate program.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
</table>
42. CHANGES TO THE HOSPITAL INPATIENT AND LONG-TERM CARE PROSPECTIVE PAYMENT SYSTEM FOR FY 2014 (CMS–1599–F)

Legal Authority: sec 1886(d) of the Social Security Act

Abstract: This annual rule revises the Medicare hospital inpatient and long-term care hospital prospective payment systems for operating and capital-related costs. This rule implements changes arising from our continuing experience with these systems.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>05/10/13</td>
<td>78 FR 27485</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>06/25/13</td>
<td></td>
</tr>
<tr>
<td>Final Action</td>
<td>08/00/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Roechel Kujawa, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Mail Stop C4–07–07, 7500 Security Boulevard, Baltimore, MD 21244

Phone: 410 786–9111

Email: roechel.kujawa@cms.hhs.gov
Department of Health and Human Services (HHS) | Completed Actions
--- | ---
Centers for Medicare & Medicaid Services (CMS) | 43. TRANSPARENCY REPORTS AND REPORTING OF PHYSICIAN OWNERSHIP OF INVESTMENT INTERESTS (CMS–5060–F)

Legal Authority: PL 111–148, sec 6002

Abstract: This final rule requires applicable manufacturers of drugs, devices, biologicals, or medical supplies covered by Medicare, Medicaid, or CHIP to annually report to the Secretary certain payments or transfers of value provided to physicians or teaching hospitals (covered recipients). In addition, applicable manufacturers and applicable group purchasing organizations (GPOs) are required to annually report certain physician ownership or investment interests.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>12/19/11</td>
<td>76 FR 78742</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>02/17/12</td>
<td></td>
</tr>
<tr>
<td>Final Action</td>
<td>02/08/13</td>
<td>78 FR 9457</td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Niall Brennan, Director, Policy and Data Analysis Group, Department of Health and Human Services, Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244

Phone: 202 690–6627

Email: niall.brennan@cms.hhs.gov

RIN: 0938–AR33
44. PART B INPATIENTS BILLINGS IN HOSPITALS (CMS–1455–F)

Legal Authority: 42 USC 1302; 42 USC 1395hh; 42 USC 1395rr (b)(1)

Abstract: This final rule revises Medicare Part B billings policies when a Part A claim for a hospital inpatient admission is denied as not medically reasonable and necessary.

Timetable:

<table>
<thead>
<tr>
<th>Action</th>
<th>Date</th>
<th>FR Cite</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPRM</td>
<td>03/18/13</td>
<td>78 FR 16632</td>
</tr>
<tr>
<td>NPRM Comment Period End</td>
<td>05/17/13</td>
<td></td>
</tr>
<tr>
<td>Merged With 0938–AR53</td>
<td>04/23/13</td>
<td></td>
</tr>
</tbody>
</table>

Regulatory Flexibility Analysis Required: Yes

Agency Contact: Twi Jackson, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244

Phone: 410 786–1159

Email: twi.jackson@cms.hhs.gov

RIN: 0938–AR73

[FR Doc. Filed 08–01–13; :00 am]

BILLING CODE 4150–24–S

[FR Doc. 2013-17060 Filed 07/22/2013 at 8:45 am; Publication Date: 07/23/2013]